Literature DB >> 12645802

Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.

Robert P Myers1, Mercedes De Torres, Françoise Imbert-Bismut, Vlad Ratziu, Frédéric Charlotte, Thierry Poynard.   

Abstract

As an alternative to liver biopsy, an index of five biochemical markers (alpha2-macroglobulin, apolipoprotein A1, haptoglobin, total bilirubin, gamma-glutamyl-transpeptidase) has been shown to predict the severity of hepatitis C-related fibrosis. The objective of this study was to compare this index with other markers frequently used for this purpose (prothrombin time, platelets, age-platelet index). In 323 hepatitis C-infected patients, the discriminative values of these markers for F2-F4 fibrosis (by the METAVIR classification) were compared. By multiple logistic regression analysis, only the five-marker index (P < 0.0001) and prothrombin time (P = 0.02) were independently predictive of F2-F4 fibrosis. For this outcome, the area under the receiver operating characteristic curve was significantly higher for the five-marker index (0.836 +/- 0.024) than the age-platelet index (P = 0.002), and the platelet count and prothrombin time (P < 0.001), indicating greater diagnostic value. The addition of the latter markers to the five-marker index proved unhelpful for increasing its accuracy. In conclusion, an index of five biochemical markers accurately predicts significant hepatitis C-related fibrosis and is superior to traditional markers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12645802     DOI: 10.1023/a:1021702902681

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

Review 1.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

2.  Which patients with hepatitis C develop liver complications?

Authors:  M H Khan; G C Farrell; K Byth; R Lin; M Weltman; J George; D Samarasinghe; J Kench; S Kaba; E Crewe; C Liddle
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

3.  A 21-year experience with major hemorrhage after percutaneous liver biopsy.

Authors:  D B McGill; J Rakela; A R Zinsmeister; B J Ott
Journal:  Gastroenterology       Date:  1990-11       Impact factor: 22.682

4.  Hepatocyte growth factor gene therapy of liver cirrhosis in rats.

Authors:  T Ueki; Y Kaneda; H Tsutsui; K Nakanishi; Y Sawa; R Morishita; K Matsumoto; T Nakamura; H Takahashi; E Okamoto; J Fujimoto
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

5.  Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups.

Authors:  T Poynard; P Bedossa
Journal:  J Viral Hepat       Date:  1997-05       Impact factor: 3.728

6.  Host genetic factors influence disease progression in chronic hepatitis C.

Authors:  E E Powell; C J Edwards-Smith; J L Hay; A D Clouston; D H Crawford; C Shorthouse; D M Purdie; J R Jonsson
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

7.  Localization of alpha 2-macroglobulin protein and messenger RNA in rat liver fibrosis: evidence for the synthesis of alpha 2-macroglobulin within Schistosoma mansoni egg granulomas.

Authors:  A M Tiggelman; W Boers; A F Moorman; P A de Boer; C M Van der Loos; J P Rotmans; R A Chamuleau
Journal:  Hepatology       Date:  1996-05       Impact factor: 17.425

8.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

9.  The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: divergent effect on interleukin-6-stimulated genes.

Authors:  M I Guillén; M J Gómez-Lechón; T Nakamura; J V Castell
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

10.  [Decrease of haptoglobin serum level in patients with chronic viral hepatitis C].

Authors:  Y Bacq; Y Schillio; J F Brechot; A De Muret; F Dubois; E H Metman
Journal:  Gastroenterol Clin Biol       Date:  1993
View more
  21 in total

Review 1.  Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care.

Authors:  Andrew J Muir
Journal:  Top Antivir Med       Date:  2014 Sep-Oct

Review 2.  Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C.

Authors:  Laurent Castera; Jean-Michel Pawlotsky
Journal:  MedGenMed       Date:  2005-11-09

3.  Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C.

Authors:  Agostino Colli; Alice Colucci; Silvia Paggi; Mirella Fraquelli; Sara Massironi; Marco Andreoletti; Vittorio Michela; Dario Conte
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

Review 4.  After the cure: management of HCV after achievement of SVR.

Authors:  Zachary A Zator; Raymond T Chung
Journal:  Curr HIV/AIDS Rep       Date:  2013-12       Impact factor: 5.071

5.  Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.

Authors:  Matthew D Sadler; Pam Crotty; Linda Fatovich; Stephanie Wilson; Harvey R Rabin; Robert P Myers
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

6.  Value of portal hemodynamics and hypersplenism in cirrhosis staging.

Authors:  Bao-Min Shi; Xiu-Yan Wang; Qing-Ling Mu; Tai-Huang Wu; Jian Xu
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

7.  Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C.

Authors:  G Usluer; N Erben; N Aykin; O Dagli; O Aydogdu; S Barut; F Cevik; B Ormen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-11       Impact factor: 3.267

8.  Relationship between clinical and pathologic findings in patients with chronic liver diseases.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Jing-Yuan Fang; Ai-Ping Cao; Mo-Bin Wan; Cheng-Zhong Li; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

9.  Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Jung-Fa Tsai; Lee-Yea Chuang; Mei-Shang Ho; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

Review 10.  Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C.

Authors:  Rudolf-E Stauber; Carolin Lackner
Journal:  World J Gastroenterol       Date:  2007-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.